T cell populations correlate with response and resistance to anti-PD-1 plus lenvatinib combination therapy in hepatocellular carcinoma

The combination of immune checkpoint blockade and tyrosine kinase inhibitors has shown promising clinical benefits, but the underlying mechanisms driving response and resistance are poorly understood. Here, we performed single-cell RNA- and TCR-sequencing, together with a HBV-peptide-barcoded single-cell RNA-sequencing approach, on paired tumor and blood samples to track the dynamic changes of T cells in HBV+ hepatocellular carcinoma (HCC) patients before or after anti-PD-1 plus lenvatinib combination therapy. We generated scRNA-seq data, scTCR-seq, and dCODE-Dextramer-seq from patients with HBV+ HCC to investigate the dynamics of immune cell subsets durint ICB treatment. Raw sequence data were provided at: China Genomic Sequence Archive (GSA), and we will provide the accession number once the paper is accepted. -------------------- Authors state: The raw data have been deposited in China Genomic Sequence Archive (GSA), and the accession number is PRJCA032479: https://ngdc.cncb.ac.cn/gsa-human/browse/HRA009324 The raw data will be released once GEO data is released for public access.